APA (7th ed.) Citation

T, P., Z, K., A, C., A, C., J, D., P, G., . . . C, B. (2017). A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Clinical colorectal cancer, 16(2), 103. https://doi.org/10.1016/j.clcc.2016.08.008

Chicago Style (17th ed.) Citation

T, Pinter, et al. "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)." Clinical Colorectal Cancer 16, no. 2 (2017): 103. https://doi.org/10.1016/j.clcc.2016.08.008.

MLA (9th ed.) Citation

T, Pinter, et al. "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)." Clinical Colorectal Cancer, vol. 16, no. 2, 2017, p. 103, https://doi.org/10.1016/j.clcc.2016.08.008.